



UNIVERZITET U BEOGRADU
HEMIJSKI FAKULTET



HELIENIQUE PASTEUR
INSTITUTE



GENOS



National and Kapodistrian
UNIVERSITY OF ATHENS



INSTITUT ZA ONKOLOGIJU
I RADIOLOGIJU SRBIJE



Vall d'Hebron
Hospital



ИНОВАЦИОНИ
ЦЕНТАР
HE



EXELIXIS
Research
Management
& Communication

siTOOLS
BIOTECH



EXPAND-EV

EXPANDING the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healthcare - 101182851

Milena Čavić

Institute for Oncology and Radiology of Serbia



BIOLAWEB

BIOLAWEB - ICPO Info dan
27.08.2025.



EXPAND-EV

Kick-off meeting, 23 January 2025



Funded by
the European Union

Project overview



Log in

English

Search

CORDIS - EU research results

[Home](#) | [Thematic Packs](#) | [Projects & Results](#) | [Videos & Podcasts](#) | [News](#) | [Datalab](#) | [Search](#)

[Home](#) > [Projects & Results](#) > [Horizon Europe](#) > EXPANDING the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healthcare



EXPANDING the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healthcare

[Fact Sheet](#)

Project Information

EXPAND-EV

Grant agreement ID: 101182851

DOI

[10.3030/101182851](https://doi.org/10.3030/101182851)

EC signature date

19 August 2024

Start date

1 January 2025

End date

31 December 2028

Funded under


Marie Skłodowska-Curie Actions (MSCA)

Total cost

No data

EU contribution

€ 1 357 000,00



Programme(s)

[HORIZON 1.2 - Marie Skłodowska-Curie Actions \(MSCA\)](#) **MAIN PROGRAMME**

Topic(s)

[HORIZON-MSCA-2023-SE-01-01 - MSCA Staff Exchanges 2023](#)

Call for proposal

[HORIZON-MSCA-2023-SE-01](#)

[See other projects for this call](#)

Funding Scheme

[HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff Exchanges](#)



EXPAND-EV

Kick-off meeting, 23 January 2025




**Funded by
the European Union**

EXPAND-EV Aims

EXPAND-EV **main goal** is to **provide a unique solution for advancing the current theranostic potential** of EVs by developing and implementing versatile, scalable and cost-effective purification system based on single-domain antibody fragments (nanobodies, NbS) as capturing agents

EXPANDing the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healthcare



EXPAND-EV Aims

EXPAND-EV is structured around two primary research areas:


Advancing Liquid Biopsy for Cancer Diagnosis


The project will validate the EV purification system in clinical laboratories using samples from breast, liver, and lung cancer patients. By analyzing the proteomic, glycomic, and transcriptomic signatures of EVs, researchers will identify new biomarker panels. These biomarkers will facilitate early cancer detection, non-invasive prognosis, and the development of personalized therapeutic strategies.

Developing Plant-Derived EVs for Drug Delivery


EXPAND-EV is pioneering the use of edible plant-derived EVs (PDEVs) as natural carriers for therapeutic small interfering RNA (siRNA) molecules. The project will establish Good Manufacturing Practice (GMP)-compliant protocols to produce these PDEVs and evaluate their safety and efficacy in preclinical cancer models. This research has the potential to create a non-invasive, sustainable, and effective drug delivery platform.

EXPAND-EV structure






MSCA SE Budget categories



MSCA SE Secondment rules

		"HOSTING" (receiving seconded staff members)			
		Academic organisation in MS/AC (1)	Non-academic organisation in MS/AC (2)	Associated Partners eligible for funding	Associated Partners non-eligible for funding
"SENDING" (sending staff members from organization)	Academic organisation in MS/AC (1)	1/3	✓	✓	✓
	Non-academic organisation in MS/AC (2)	✓	1/3	✓	✓
	Associated Partners* eligible for funding	✓	✓	✗	✗
	Associated Partners non-eligible for funding	✗	✗	✗	✗

 This symbol refers to same sector secondments up to 1/3 of the total implemented secondments funded by the EU as long as they are demonstrated to be interdisciplinary.

* Associated Partners eligible for funding (see List of Participating Countries in Horizon Europe)



EXPAND-EV challenges Year 1

Amendment in the first year

Budget issues – national and internal regulations

Seconded staff – availability of staff

Sending institutions – feasibility of staff for travel

Cross-checking yearly secondment months (fluidity of host institutions)

Personnel changes

Unpredictability of staff personal issues



EXPAND-EV

HOME

About

News

Consortium

Publications

Contact

Private Area



EXPANDing the value of Extracellular Vesicles

as carriers of biomarker and therapy in precision healthcare

https://www.instagram.com/expand_ev_msca/?igsh=bXFqbzc1YTZ4Mm94

<https://www.linkedin.com/showcase/expand-ev-eu-project/posts/?feedView=all>



EXPAND-EV

Kick-off meeting, 23 January 2025



Funded by
the European Union

milena.cavic@ncrc.ac.rs

www.stepupiors.eu

STEPUPIORS

Twinning for a European Consortium of Rectal Cancer Research Institutions through Stepping up Scientific, Technological and Innovation Excellence of IORS



Funded by
the European Union

Project number: 101079217



INSTITUT ZA ONKOLOGIJU
I RADIOLOGIJU SRBIJE



stepupiors

stepupiors

stepupiors@gmail.com

@stepupiors



This study was funded by the Horizon Europe Twinning Project STEPUPIORS – 101079217.
The contents of this presentation do not necessarily reflect the position or opinion of the European Commission.



Funded by
the European Union